Autopsy report · NCT00623727
BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A
Cause of deathNo reason given
Life of this trial
- Registered 5 months before it started.
- Ran for about 2 years 4 months before it stopped.
- 143 participants enrolled.
- Results were posted on the registry 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Bayer
- Sponsor type
- Industry
- Conditions
- Hemophilia A
- Interventions
- rFVIII-FS/pegylated liposomes (BAY79-4980); rFVIII-FS/WFI (BAY14-2222)
- Participants
- 143
- Sites
- 95
- Countries
- Argentina, Australia, Austria, Belgium, Canada, Chile, Croatia, Denmark, Estonia, France, Germany, Israel and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.